{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:14:12Z","timestamp":1763388852648},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/fpc.0b013e3283653afc","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T12:19:20Z","timestamp":1377001160000},"page":"597-604","source":"Crossref","is-referenced-by-count":24,"title":["ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin\/5-FU-based neoadjuvant therapy"],"prefix":"10.1097","volume":"23","author":[{"given":"Enrica","family":"Rumiato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cavallin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Boldrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Cagol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Castoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ermanno","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ruol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Saggioro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210213","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012.","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R2-3-20210213","first-page":"CD001556","article-title":"Preoperative chemotherapy for resectable thoracic esophagealcancer.","volume":"2006","author":"Vogt","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-3-20210213","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrclinonc.2011.121","article-title":"Predictive biomarkers: a paradigm shift towards personalized cancer medicine.","volume":"8","author":"La Thangue","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-3-20210213","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrclinonc.2010.168","article-title":"Targeted therapies: tyrosine-kinase inhibitors - new standard for NSCLC therapy.","volume":"7","author":"Saijo","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"R5-3-20210213","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1634\/theoncologist.2010-0258","article-title":"Part 1: background, methodology, and clinical adoption of pharmacogenetics.","volume":"16","author":"Deenen","year":"2011","journal-title":"Oncologist"},{"key":"R6-3-20210213","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1634\/theoncologist.2010-0259","article-title":"Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.","volume":"16","author":"Deenen","year":"2011","journal-title":"Oncologist"},{"key":"R7-3-20210213","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1634\/theoncologist.2010-0260","article-title":"Part 3: pharmacogenetic variability in phase II anticancer drug metabolism.","volume":"16","author":"Deenen","year":"2011","journal-title":"Oncologist"},{"key":"R8-3-20210213","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1634\/theoncologist.2010-0261","article-title":"Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.","volume":"16","author":"Deenen","year":"2011","journal-title":"Oncologist"},{"key":"R9-3-20210213","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200645030-00003","article-title":"Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.","volume":"45","author":"Bosch","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R10-3-20210213","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0305-7372(98)90056-1","article-title":"Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.","volume":"24","author":"Reed","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"R11-3-20210213","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2009.45","article-title":"Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.","volume":"10","author":"Khrunin","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"R12-3-20210213","first-page":"4899","article-title":"Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.","volume":"62","author":"Furuta","year":"2002","journal-title":"Cancer Res"},{"key":"R17-3-20210213","first-page":"555","article-title":"Comparison of two human ovarian carcinoma cell lines (A2780CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.","volume":"16","author":"Yu","year":"2000","journal-title":"Int J Oncol"},{"key":"R23-3-20210213","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/annonc\/mdr324","article-title":"The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.","volume":"23","author":"Erculj","year":"2012","journal-title":"Ann Oncol"},{"key":"R27-3-20210213","first-page":"6004","article-title":"Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.","volume":"63","author":"Kawakami","year":"2003","journal-title":"Cancer Res"},{"key":"R30-3-20210213","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate - a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Statist Soc B"},{"key":"R33-3-20210213","first-page":"1091","article-title":"ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.","volume":"32","author":"Kamikozuru","year":"2008","journal-title":"Int J Oncol"},{"key":"R34-3-20210213","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/138920209788488544","article-title":"Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair.","volume":"10","author":"Zhang","year":"2009","journal-title":"Curr Genomics"},{"key":"R40-3-20210213","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/bjc.2013.83","article-title":"ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.","volume":"108","author":"Li","year":"2013","journal-title":"Br J Cancer"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0b013e3283653afc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T21:49:51Z","timestamp":1715896191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201311000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e3283653afc","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}